T-cell prolymphocytic leukemia
| Section editor | |
|---|---|
 |
Bhagirathbhai Dholaria, MBBS Vanderbilt University Nashville, TN |
5 regimens on this page
5 variants on this page
|
Guidelines
NCCN
TPLL-ISG
- 2019: Staber et al. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia
All lines of therapy
Alemtuzumab monotherapy
| back to top |
Regimen
| Study | Evidence |
|---|---|
| Dearden et al. 2001 | Non-randomized |
| Dearden et al. 2011 | Non-randomized |
Chemotherapy
References
- Dearden CE, Matutes E, Cazin B, Tjønnfjord GE, Parreira A, Nomdedeu B, Leoni P, Clark FJ, Radia D, Rassam SM, Roques T, Ketterer N, Brito-Babapulle V, Dyer MJ, Catovsky D. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001 Sep 15;98(6):1721-6. link to original article PubMed
- Dearden CE, Khot A, Else M, Hamblin M, Grand E, Roy A, Hewamana S, Matutes E, Catovsky D. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood. 2011 Nov 24;118(22):5799-802. Epub 2011 Sep 26. link to original article PubMed